These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

577 related items for PubMed ID: 22465746

  • 1. Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase.
    Schmeisser F, Adamo JE, Blumberg B, Friedman R, Muller J, Soto J, Weir JP.
    Vaccine; 2012 May 14; 30(23):3413-22. PubMed ID: 22465746
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Fabrication of influenza virus-like particles using M2 fusion proteins for imaging single viruses and designing vaccines.
    Wei HJ, Chang W, Lin SC, Liu WC, Chang DK, Chong P, Wu SC.
    Vaccine; 2011 Sep 22; 29(41):7163-72. PubMed ID: 21651946
    [Abstract] [Full Text] [Related]

  • 4. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
    Mahmood K, Bright RA, Mytle N, Carter DM, Crevar CJ, Achenbach JE, Heaton PM, Tumpey TM, Ross TM.
    Vaccine; 2008 Oct 03; 26(42):5393-9. PubMed ID: 18706956
    [Abstract] [Full Text] [Related]

  • 5. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.
    Kreijtz JH, Suezer Y, de Mutsert G, van den Brand JM, van Amerongen G, Schnierle BS, Kuiken T, Fouchier RA, Löwer J, Osterhaus AD, Sutter G, Rimmelzwaan GF.
    J Infect Dis; 2009 Feb 01; 199(3):405-13. PubMed ID: 19061423
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge.
    Haynes JR, Dokken L, Wiley JA, Cawthon AG, Bigger J, Harmsen AG, Richardson C.
    Vaccine; 2009 Jan 22; 27(4):530-41. PubMed ID: 19026705
    [Abstract] [Full Text] [Related]

  • 8. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1.
    Kreijtz JH, Suezer Y, van Amerongen G, de Mutsert G, Schnierle BS, Wood JM, Kuiken T, Fouchier RA, Lower J, Osterhaus AD, Sutter G, Rimmelzwaan GF.
    J Infect Dis; 2007 Jun 01; 195(11):1598-606. PubMed ID: 17471429
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
    Pavlova SP, Veits J, Keil GM, Mettenleiter TC, Fuchs W.
    Vaccine; 2009 Jan 29; 27(5):773-85. PubMed ID: 19041677
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
    Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y, Kpamegan E, Courbron D, Fries LF, Glenn GM.
    Vaccine; 2013 Sep 13; 31(40):4305-13. PubMed ID: 23891795
    [Abstract] [Full Text] [Related]

  • 14. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM.
    Vaccine; 2007 May 10; 25(19):3871-8. PubMed ID: 17337102
    [Abstract] [Full Text] [Related]

  • 15. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses.
    Kreijtz JH, Suezer Y, de Mutsert G, van den Brand JM, van Amerongen G, Schnierle BS, Kuiken T, Fouchier RA, Löwer J, Osterhaus AD, Sutter G, Rimmelzwaan GF.
    Vaccine; 2009 Oct 23; 27(45):6296-9. PubMed ID: 19840663
    [Abstract] [Full Text] [Related]

  • 16. Mucosal administration of raccoonpox virus expressing highly pathogenic avian H5N1 influenza neuraminidase is highly protective against H5N1 and seasonal influenza virus challenge.
    Kingstad-Bakke B, Kamlangdee A, Osorio JE.
    Vaccine; 2015 Sep 22; 33(39):5155-62. PubMed ID: 26271828
    [Abstract] [Full Text] [Related]

  • 17. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
    Ryder AB, Buonocore L, Vogel L, Nachbagauer R, Krammer F, Rose JK.
    J Virol; 2015 Mar 22; 89(5):2820-30. PubMed ID: 25540378
    [Abstract] [Full Text] [Related]

  • 18. Influenza virus-like particle vaccines.
    Haynes JR.
    Expert Rev Vaccines; 2009 Apr 22; 8(4):435-45. PubMed ID: 19348559
    [Abstract] [Full Text] [Related]

  • 19. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine.
    Crevar CJ, Ross TM.
    Virol J; 2008 Oct 28; 5():131. PubMed ID: 18957098
    [Abstract] [Full Text] [Related]

  • 20. Virus-like particle vaccine comprised of the HA, NA, and M1 proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice.
    Tao P, Luo M, Zhu D, Qu S, Yang Z, Gao M, Guo D, Pan Z.
    Viral Immunol; 2009 Jul 28; 22(4):273-81. PubMed ID: 19594398
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.